S1451 Relationship Between Clinical and Histologic Findings With Tulisokibart Induction at Week 12 and Maintenance Dosing at Week 50 in the Phase 2 Randomized Controlled ARTEMIS-UC Study in Participants With Ulcerative Colitis

Le résumé fourni par la source

Introduction: Although histologic remission has been associated with improved long-term outcomes in ulcerative colitis (UC), histology is inconsistently performed and heterogeneously evaluated in routine clinical care as an assessment of remission depth. Methods: We evaluated the correlation between changes in clinical/biomarker/endoscopic and histologic endpoints following tulisokibart treatment over 50 weeks. ARTEMIS-UC enrolled 2 cohorts based on a genetic diagnostic test (Dx) for anti-TL1A treatment response: Cohort 1 (participants regardless of Dx results) and Cohort 2 (only Dx positive participants). We examined 15 relationships between 5 clinical/endoscopic/biomarker endpoints and 3 histologic endpoints at Week 12 (W12) after induction (Cohort 1) and Week 50 (W50) (Cohorts 1 and 2) among induction responders continuing maintenance tulisokibart. Histologic endpoints included histologic improvement, histologic-endoscopic mucosal improvement (HEMI), and mucosal healing assessed in the Histology Analysis Set (HAS). Clinical/endoscopic/biomarker endpoints included Modified Mayo Score for clinical remission/clinical response/endoscopic improvement/normalization of fecal calprotectin and hsCRP normalization. The Phi correlation coefficient assessed pairwise correlations between clinical/endoscopic/biomarker and histologic endpoints. Results: There were 65 and 34 tulisokibart participants included in the HAS population for the W12 and W50 analyses, respectively. The strongest correlations were the following: endoscopic improvement: HEMI, endoscopic improvement: mucosal healing, clinical remission: HEMI, and clinical remission: mucosal healing, all >0.8 at W12 (post-induction in Cohort 1) and >0.9 at W50 (post-maintenance dosing in Cohorts 1 and 2). Normalization of fecal calprotectin also demonstrated a strong correlation with histologic endpoints (>0.7) at W50. Conclusion: Strong correlations exist between clinical/endoscopic and histologic endpoints after 12 weeks of induction therapy with tulisokibart, followed by 38 weeks of maintenance therapy in induction responders. These findings underscore the potential for clinical remission to reflect endoscopic and histologic healing in patients with UC, which may enhance patient management strategies and a more comprehensive understanding of treatment efficacy. Moreover, these findings indicate the potential of tulisokibart in achieving deep remission in patients with UC.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.